New Areas of Harmonisation Adopted Alongside Significant Advancement of Ongoing Activities
The Assembly of the International Council for Harmonisation (ICH) met in-person on 13 & 14 May 2025, in Madrid, Spain in parallel of meetings of 11 Working Groups, and...
IGBA Welcomes ICH New Topic for Harmonisation: Framework for Determining Utility of Comparative Efficacy Studies in Biosimilar Development Programs
The International Generic and Biosimilar medicines Association (IGBA) commends the General Assembly of the International Council for Harmonisation of Technical Requirements for...
The IGBA CEO Advisory Committee: Four Keys to More Predictable Supply Chains
Vienna, June 14, 2023 - The COVID-19 pandemic demonstrated the critical importance of resilient global supply chains. As the CEO Advisory Committee of the International Generic...
Generic and Biosimilar Medicines, Central to Patient Health and Global Healthcare Policies
Experts and leaders from the local and global generic and biosimilar medicines industry, Government and UN agencies, patient organizations, academia and other stakeholders are...
IGBA’s Newly Launched CEO Advisory Committee Holds Inaugural Meeting with WTO Director General
The newly established IGBA CEO Advisory Committee, a forum for generic and biosimilar medicines industry leaders to discuss broad, strategic issues, and to engage and...
Vivian Frittelli takes over the position of IGBA Chair
IGBA, the International Generic and Biosimilar Medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Vivian...
IGBA establishes a CEO Advisory Committee
The International Generic and Biosimilar medicines Association (IGBA) announced today that it has established a CEO Advisory Committee composed of...
Generics and biosimilars – champion cost-savers in the healthcare industry
By courtesy of and issued by: BONITAS Medical Aid It is common knowledge that healthcare costs rise exponentially and medical schemes have to find ways to reduce costs both for...